Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00001656

Enrollment

Registered

1999-11-04

Start date

1997-06-30

Completion date

2008-06-30

Last updated

2011-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Schizophrenia, Psychotic Disorder, Schizophrenia

Keywords

Clozapine, Olanzapine, Drug Response, Safety, Childhood Onset Schizophrenia, Schizoaffective Disorder, Multidimensionally Impaired Syndrome, Phenomenology, Biochemical Correlates, Brain Imaging, Schizophrenia, Childhood Schizophrenia, Psychosis

Brief summary

The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses. Childhood psychosis is a serious disorder that may have devastating consequences. Effective treatments for the condition are under continual investigation. This study will examine the causes of and offer treatment for childhood psychosis. Participants in this study will undergo psychological tests, blood and urine tests, electroencephalogram (EEG), electrocardiogram (EKG), and magnetic resonance imaging (MRI) scans of the brain for the first 1 to 2 weeks of the study while taking their regular medications. Participants will then be tapered off their medications over 1 to 3 weeks and will continue to stay off medications for an additional 2 days to 3 weeks. During this time, participants will undergo psychiatric, neurological, and cardiac examinations as well as blood tests. After this period without medications, participants will be randomly assigned to receive either clozapine or olanzapine for 8 weeks. An EEG will be performed prior to treatment and after 6 weeks of study medication. Participants who respond well to the study drugs may continue to receive them through their own physician. Participants who do not respond to either clozapine or olanzapine or cannot tolerate their side effects will be treated individually with other drugs until optimum treatment is identified. Regular telephone updates and in person visits to NIH for repeat testing and MRIs will be conducted.

Detailed description

The purpose of this protocol is to compare efficacy of clozapine and olanzapine in children and adolescents with schizophrenia and psychoses, as well as to learn about side effects of these medication in pediatric population. The underlying hypothesis is that clozapine has superior efficacy over olanzapine. Children and adolescents, ages 7 to 18 years, meeting DSM-IV criteria for schizophrenia, schizoaffective disorder and psychotic disorder not otherwise specified, with onset of psychosis before their 13th birthday, who have not responded to at least two prior trials with typical or a typical neuroleptics, will be eligible to participate in a double-blind, parallel group, trial of olanzapine-clozapine. This study will be done in conjunction with the Screening protocol, which will include characterization by clinical phenomenology, eye tracking, MRI brain imaging, plasma biochemistry, and chromosomal analysis. This study will consist of the following phases 1) Tapering of psychotropic medications (1-4 weeks, depending upon type and dosage). 2) Observation for up to 2 weeks drug free, in order to establish a baseline prior to starting medication trial. 3) An 8 week double-blind trial of either clozapine or olanzapine. Efficacy and tolerability of clozapine and olanzapine will be compared using specified criteria. 4) If desired improvement not achieved or trial is interrupted, an 8 week open trial of the second medication and 5) Discharge following medication optimization for up to 4 weeks, or as clinically appropriate. This protocol also includes a follow-up every 2 to 3 years for a period of 10 years.

Interventions

DRUGOlanzapine

tablet; 5-20mg/day; 8 weeks

DRUGClozapine

tablet; 12.5-900mg/day; 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

7 Years to 18 Years

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: Males and females, age 7 to 18 years Onset of psychotic symptoms before 13th birthday and a DSM-IV diagnosis of either schizophrenia, schizoaffective disorder, MDI syndrome, or psychosis NOS (not otherwise specified). Current significant impairment due to the illness (current psychotic symptoms, decline of functioning academically and socially, significant discomfort due to psychotic symptoms). Failure of two prior trials with antipsychotic medications (either typical or atypical) used at adequate doses (greater than or equal to 100 mg/day in chlorpromazine equivalents) and for adequate duration (at least 4 weeks, unless terminated due to intolerable side effects). Failure is defined as either insufficient response with persistence of symptoms significantly impairing child's functioning, according to child's and parental reports and medical and school records, or intolerable side effects to drugs other than clozapine and olanzapine. Subjects may be included if their previous trial(s) of olanzapine failed to reach the dose of 20. mg/day or a duration of fewer than four weeks. Subjects may be included if their previous trial(s) of clozapine failed to reach the dose of 200. mg/day or a duration of fewer than six weeks. Comorbid psychiatric disorders in the past 12 months are permitted as long as not clinically significant.

Exclusion criteria

Prepsychotic full-scale IQ less than 70. Unstable major neurological or medical conditions. Current pregnancy or plan to become pregnant during the first three months (the duration of the study) in woman of childbearing age; breast-feeding in woman with infants. DSM-IV substance abuse or dependence in the past 6 months. True non-responders to either olanzapine or clozapine. True non-response is defined as: a) intolerance to either of the medications preventing an adequate trial, or b) only minimal (less than 20%) benefit with the adequate trial of either of the medications. Adequate trial constitutes at least 8 weeks of the medication with the dose of 20 mg on olanzapine or 200 mg of clozapine.

Design outcomes

Primary

Measure	Time frame	Description
Change in the Bunney-Hamburg Rating Scale for Anxiety	8 week double-blind study period; baseline and 8 weeks	Measures change in the severity of anxiety; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
Change in the Scale for the Assessment of Positive Symptoms	8 week double-blind study period; baseline and 8 weeks	Measures change in hallucinations, delusions, bizarre behavior, and thought organization. Minimum score = 0; maximum score = 170; lower score is considered a better outcome.
Change in the Bunney-Hamburg Rating Scale for Psychosis	8 week double-blind study period; baseline and 8 weeks	Measures change in psychosis severity; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
Change in Bunney-Hamburg Rating Scale for Depression	8 week double-blind study period; baseline and 8 weeks	Measures change in severity of depression; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
Change in Bunney-Hamburg Rating Scale for Mania	8 week double-blind study period; baseline and 8 weeks	Measures change in the severity of mania; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.
Change in the Scale for the Assessment of Negative Symptoms	8 week double-blind study period; baseline and 8 weeks	Measures change in affective flattening or blunting, alogia, avolition/apathy, anhedonia/asociality, attention; minimum score = 0; maximum score = 125; lower values are considered a better outcome
Change in the Clinical Global Impression Severity of Symptoms Scale	8 week double-blind study period; baseline and 8 weeks	Measures change in the severity of symptoms; Minimum score = 1; maximum score = 7; lower score is considered a better outcome.
Change in the Brief Psychiatric Rating Scale-24	8 week double-blind study period; baseline and 8 weeks	A 24-item scale measuring change in interpersonal behaviors, mood, psychosis, anxiety, speech, sleep, orientation and physical activity. Lowest score = 24; highest score = 168; lower score is considered a better outcome.

Other

Measure	Time frame	Description
Change in Body Mass Index (BMI)	8 week double-blind study period; baseline and 8 weeks	BMI is calculated by the following formula: weight (in kilograms) divided by the square of the height (in meters)
Change in Extrapyramidal Movements as Measured by the Abnormal Involuntary Movements Scale (AIMS)	8 week double-blind study period; baseline and 8 weeks	minimum score = 10; maximum score = 50; lower score is considered a more favorable outcome
Change in Extrapyramidal Movements as Measured by the Simpson Angus Scale Score	8 week double-blind study period; baseline and 8 weeks	minimum score = 10; maximum score = 90; lower score considered a more favorable outcome
Change in Weight	8 week double-blind study period; baseline and 8 weeks	—

Countries

United States

Participant flow

Participants by arm

Arm	Count
Olanzapine Group All medications were given by mouth, in identical tablet form. Day 1, patient was given 5mg olanzapine or 12.5mg clozapine. Clozapine dose was then increased every other day, the first increase by 12.5mg (to a total dose of 25mg/day) and then in steps of 25mg. When the clozapine dose reached 150mg/day, the olanzapine dose was increased to 10mg/day. When the clozapine dose reached 300mg/day, the olanzapine dose was increased to 15mg/day. Further increases were guided by clinical judgment to a maximum of 20mg/day of olanzapine and 900mg/day of clozapine.	13
Clozapine Group All medications were given by mouth, in identical tablet form. Day 1, patient was given 5mg olanzapine or 12.5mg clozapine. Clozapine dose was then increased every other day, the first increase by 12.5mg (to a total dose of 25mg/day) and then in steps of 25mg. When the clozapine dose reached 150mg/day, the olanzapine dose was increased to 10mg/day. When the clozapine dose reached 300mg/day, the olanzapine dose was increased to 15mg/day. Further increases were guided by clinical judgment to a maximum of 20mg/day of olanzapine and 900mg/day of clozapine.	12
Total	25

Baseline characteristics

Characteristic	Total	Olanzapine Group	Clozapine Group
Age, Categorical <=18 years	25 Participants	13 Participants	12 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	0 Participants	0 Participants	0 Participants
Age Continuous	12.2 years STANDARD_DEVIATION 2.1	12.8 years STANDARD_DEVIATION 2.4	11.7 years STANDARD_DEVIATION 2.3
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	1 Participants	1 Participants	0 Participants
Race (NIH/OMB) Black or African American	7 Participants	4 Participants	3 Participants
Race (NIH/OMB) More than one race	1 Participants	1 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants	0 Participants	1 Participants
Race (NIH/OMB) White	15 Participants	7 Participants	8 Participants
Region of Enrollment United States	25 participants	13 participants	12 participants
Sex: Female, Male Female	10 Participants	6 Participants	4 Participants
Sex: Female, Male Male	15 Participants	7 Participants	8 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	13 / 13	12 / 12
serious Total, serious adverse events	1 / 13	2 / 12

Outcome results

Primary

Change in Bunney-Hamburg Rating Scale for Depression

Measures change in severity of depression; Minimum score = 0; maximum score = 7; lower score is considered a better outcome.